Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers.

Davy M, Bird N, Rost KL, Fuder H.

Chemotherapy. 1999 Nov-Dec;45(6):491-5.

PMID:
10567780
2.

Lack of effect of gemifloxacin on the steady-state pharmacokinetics of theophylline in healthy volunteers.

Davy M, Allen A, Bird N, Rost KL, Fuder H.

Chemotherapy. 1999 Nov-Dec;45(6):478-84.

PMID:
10567778
3.

Lack of pharmacokinetic interaction between gemifloxacin and digoxin in healthy elderly volunteers.

Vousden M, Allen A, Lewis A, Ehren N.

Chemotherapy. 1999 Nov-Dec;45(6):485-90.

PMID:
10567779
4.

Warfarin pharmacodynamics unaffected by cilomilast.

Kelly J, Murdoch RD, Clark DJ, Webber DM, Fuder H.

Ann Pharmacother. 2001 Dec;35(12):1535-9.

PMID:
11793614
5.

Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers.

Allen A, Bygate E, Vousden M, Oliver S, Johnson M, Ward C, Cheon A, Choo YS, Kim I.

Antimicrob Agents Chemother. 2001 Feb;45(2):540-5.

6.

Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers.

Allen A, Vousden M, Lewis A.

Chemotherapy. 1999 Nov-Dec;45(6):496-503.

PMID:
10567781
7.

Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.

Vaz-da-Silva M, Almeida L, Falcão A, Soares E, Maia J, Nunes T, Soares-da-Silva P.

Clin Ther. 2010 Jan;32(1):179-92. doi: 10.1016/j.clinthera.2010.01.014.

PMID:
20171423
8.

Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin.

Ragueneau-Majlessi I, Levy RH, Meyerhoff C.

Epilepsy Res. 2001 Nov;47(1-2):55-63.

PMID:
11673021
9.

The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.

Schwartz JI, Bugianesi KJ, Ebel DL, De Smet M, Haesen R, Larson PJ, Ko A, Verbesselt R, Hunt TL, Lins R, Lens S, Porras AG, Dieck J, Keymeulen B, Gertz BJ.

Clin Pharmacol Ther. 2000 Dec;68(6):626-36.

PMID:
11180023
10.

Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers.

Allen A, Bygate E, Oliver S, Johnson M, Ward C, Cheon AJ, Choo YS, Kim IC.

Antimicrob Agents Chemother. 2000 Jun;44(6):1604-8.

11.

Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.

Malhotra B, Alvey C, Gong J, Li X, Duczynski G, Gandelman K.

Br J Clin Pharmacol. 2011 Aug;72(2):257-62. doi: 10.1111/j.1365-2125.2011.03989.x.

12.

Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting.

Weiss D, Knight R, Zhou S, Palmisano M, Chen N.

Clin Drug Investig. 2015 Jul;35(7):455-61. doi: 10.1007/s40261-015-0299-1.

PMID:
26024727
13.

Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin.

Yu CY, Campbell SE, Zhu B, Knadler MP, Small DS, Sponseller CA, Hunt TL, Morgan RE.

Curr Med Res Opin. 2012 Feb;28(2):187-94. doi: 10.1185/03007995.2011.648264. Epub 2012 Jan 9.

PMID:
22149769
14.

Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects.

Yin OQ, Gallagher N, Fischer D, Zhao L, Zhou W, Leroy E, Golor G, Schran H.

Clin Drug Investig. 2011;31(3):169-79. doi: 10.2165/11538700-000000000-00000.

PMID:
21184622
15.

Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

Krishna R, Stypinski D, Ali M, Garg A, Cote J, Maes A, Degroot B, Liu Y, Li S, Connolly SM, Wagner JA, Stoch SA.

Br J Clin Pharmacol. 2012 Jul;74(1):116-24. doi: 10.1111/j.1365-2125.2012.04171.x.

16.

Eprosartan does not affect the pharmacodynamics of warfarin.

Kazierad DJ, Martin DE, Ilson B, Boike S, Zariffa N, Forrest A, Jorkasky DK.

J Clin Pharmacol. 1998 Jul;38(7):649-53.

PMID:
9702851
17.

Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin.

Depré M, Van Hecken A, Oeyen M, De Lepeleire I, Laethem T, Rothenberg P, Petty KJ, Majumdar A, Crumley T, Panebianco D, Bergman A, de Hoon JN.

Eur J Clin Pharmacol. 2005 Jul;61(5-6):341-6. Epub 2005 Jun 28.

PMID:
15983826
18.

Evaluation of phototoxic potential of gemifloxacin in healthy volunteers compared with ciprofloxacin.

Vousden M, Ferguson J, Richards J, Bird N, Allen A.

Chemotherapy. 1999 Nov-Dec;45(6):512-20.

PMID:
10567783
19.

Impact of gemifloxacin on the normal human intestinal microflora.

Barker PJ, Sheehan R, Teillol-Foo M, Palmgren AC, Nord CE.

J Chemother. 2001 Feb;13(1):47-51.

PMID:
11233800
20.

A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context.

Ball P, Mandell L, Patou G, Dankner W, Tillotson G.

Int J Antimicrob Agents. 2004 May;23(5):421-9. Review.

PMID:
15120718

Supplemental Content

Support Center